Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: Results from a large tertiary care hospital

Sumitra Shantakumar,[1] Yu-Fan Ho,[1] Li-Wen Tuan,[2] Tzu-Mei Lin,[3] Yi-Hsing Chen[3]

Abstract

Background: Burden of severe eosinophilic asthma (SEA) data in Asia are limited.

Objective: This retrospective, observational study characterized SEA epidemiology, healthcare resource use (HCRU) and costs for adult patients in Taiwan.

Methods: Data from Taichung Veterans General Hospital electronic medical record database, between 2013 to 2016, were extracted. Eligible general asthma patients were ≥ 18 years at index date, with ≥ 1 medical claim with an asthma diagnosis after the index date. Patients with SEA (meeting additional criteria: Global Initiative for Asthma Step 4/5 treatment guidelines [within 3 months preceding index date], ≥ 2 clinically significant exacerbations, and eosinophil counts ≥ 300 cells/μL [within 12 months preceding index date] or ≥ 150 cells/μL [on index date]) and SEA patients using high-dose inhaled corticosteroids (HD ICS) were also identified. Twelve months' pre-index data were used to evaluate exacerbation frequency, treatment patterns, HCRU, and costs (2016 US Dollars).

Results: Of 2,601 eligible general asthmatic patients, 162 (6.2%) met predefined criteria for SEA; of SEA patients, 72/162 (44.4%) had used HD ICS. SEA and HD ICS SEA patients experienced more clinically significant exacerbations than general asthma patients (1.6 ± 3.3 and 1.5 ± 2.6 vs 0.6 ± 2.0, $p < 0.01$). HD ICS SEA and SEA patients incurred at least 2–2.5-fold higher total asthma-related and all-cause costs than general asthma patients and had significantly greater HCRU.

Conclusions: Of eligible Taiwanese general asthma patients, 6.2% met predefined SEA criteria. Compared with general asthma patients, SEA and HD ICS SEA patients used more respiratory medications, experienced more exacerbations, and incurred greater HCRU and higher costs.

Key words: severe eosinophilic asthma, high-dose inhaled corticosteroids, Taiwan, epidemiology, health care costs

From:
1 Department of Epidemiology, GlaxoSmithKline,
   GSK Asia House, Singapore
2 Formosa Biomedical Technology Corp. CRO Division, Taipei, Taiwan
3 Taichung Veterans General Hospital, Taichung, Taiwan

Corresponding author:
Yi-Hsing Chen
Chief of the Division of Allergy, Immunology and Rheumatology at
Taichung Veterans General Hospital, Taichung, Taiwan
E-mail: dr.yihsing@gmail.com

Introduction

Most asthma cases are controlled with available medication or stepped up if they remain uncontrolled. For patients with Severe Asthma (SA), however, most still have poor asthma control, persistent airflow limitation, and frequent severe exacerbations.[1,2]

Estimates, predominantly from Western countries, indicate low prevalence of SA (5–10%),[1] however, this group contributes to disproportionally high health-care resource use (HCRU, ~50%) due to treatment of frequent acute exacerbations.[3] Compared with controlled asthma, uncontrolled disease imposes substantial direct and indirect costs through lost working days,[4] increased total and asthma-related health-care costs,[5,6] decreased health-related quality of life,[7,8] and increased risk of death.[9] As current therapies do not adequately control symptoms for all patients with SA, there is an unmet need for therapeutic options to reduce SA-related morbidity and mortality.

Severe eosinophilic asthma (SEA), associated with elevated blood and sputum eosinophil counts,[1,10,11] and severe allergic (immunoglobulin [Ig]E-mediated) asthma (SAA), are SA phenotypes that can overlap leading to overlap in treatment eligibility.[12] Clinical characterization of SEA patients, and examination of their associated HCRU, has been conducted in Western countries but are poorly described in Asia. This study aimed to characterize the epidemiology and clinical characteristics of adult patients with SEA in Taiwan, to describe dispensed medications, HCRU and associated asthma-related and all-cause costs.

Methods

Objectives

To estimate the prevalence of asthmatic patients in Taiwan meeting SEA criteria, describe patient demographics, clinical characteristics, respiratory medication use, and quantify HCRU and costs (all-cause and asthma-related) over 12-months.

Study design

This retrospective population study utilized data from July 1st, 2013 through June 30th, 2016, obtained from the Taichung Veterans General Hospital (VGHTC) electronic medical record (EMR) database (see **Appendix S1**). The VGHTC is a large tertiary center with up to 190 million outpatient visits annually and a high proportion of returning patients. Exacerbation frequency, treatment patterns and HCRU/costs were assessed post-index period (index was defined as the date with the first confirmed diagnosis of asthma after July 1st, 2014; **Figure S1**).

Patient Cohort Identification

Included patients were: ≥ 18 years at index date, with a record of ≥ 1 medical claim with an asthma diagnosis (International Classification of Diseases-9: 493.xx; -10: J45 or J46, see **Appendix S1**) after July 1st, 2014, minimum of 12 months' medical data available before (baseline) and after (follow-up) the index date for a total of 24 months. Patients with chronic obstructive pulmonary disease (COPD) and smokers were not excluded (see **Appendix S1**).

Patients were further classified as having SEA if they: met the criteria for GINA Step 4 or 5 treatment guidelines[13] in the 3 months prior to index date, had ≥ 2 clinically significant exacerbations in the 12 months prior to index date, and had ≥ 1 blood eosinophil count (BEC) result of ≥ 300 cells/μL (steady state or exacerbated state) in the 12 months prior to index date, OR ≥ 150 cells/μL measured on index date. Patients meeting SEA criteria were stratified by the following BEC ranges: < 150, 150–300, > 300–400, and > 400 cells/μL. As there is currently no gold standard for defining eosinophilic asthma severity,[14] different cut-offs were explored to define SEA and to determine the corresponding effect on the prevalence.

A subset of SEA population who had ever been treated with HD ICS was also extracted and analyzed.

Patients meeting the SEA criteria were additionally classified based on the number of exacerbations and their use of oral corticosteroid (OCS).

Study procedures and evaluations

See **Appendix S1** for further details.

Demographics and clinical characteristics

These were described for patients at study index date.

Exacerbations

Clinically significant asthma exacerbations were recorded during the 12-month follow-up period (inclusive of index date) and were defined as an asthma-related ED visitor hospital admission, or an exacerbation treated with OCS.

Asthma medication

Asthma medication exposure, including pattern of medication use, adherence, and OCS average daily dose, were defined as:

> **Medication use**: The distribution of patients prescribed ≥ 1 asthma medications over the 12-month index period were summarized.
>
> **Medication adherence**: Adherence to controller therapy at index date was assessed over 365 days using proportion of days covered (PDC).
>
> **OCS average daily dose:** The average daily dose for OCS was described for OCS episodes (defined as a sequence of OCS claims that occurred ≤ 7 days apart).

Healthcare resource use

Asthma-related HCRU data (encompassing medical claims with an asthma diagnosis in the primary position) were examined during the 12-month follow-up period (inclusive of index date). Frequency of out-patient department (OPD) visits, ED visits, hospitalizations (≥ 1 day to distinguish from patients who received diagnostic services or procedures), average length of stay, and intensive care unit (ICU) admission (Yes/No) were analyzed.

All-cause and asthma-related healthcare costs

Healthcare costs comprised all medical fees (medication, examination, surgeries, inpatient hospital admissions, OPD, ER, wards, etc.) charged to the patient.

Statistical analysis

For medication adherence, PDC was multiplied by 100 to yield a percentage and categorized as high (> 80%), medium (80% ≥ PDC ≥ 50%), low (50% > PDC ≥ 30%), and very low (< 30%) based on published literature.[15,16]

For HCRU, frequency rates (number of events/person/year) were evaluated. For economic endpoints, asthma-related healthcare costs paid to providers were computed per patient annually and applied to costs of hospitalization, OPD visits, and ED visits. Costs were standardized and reported in 2016 US dollars using the Medical Care Consumer Price Index. A non-parametric bootstrap procedure was used to carry out statistical inference and determine *p*-values for the cost difference between exposure groups (see **Appendix S1** for bootstrapping algorithm).

Economic outcomes, demographics and clinical characteristics were summarized by descriptive statistics (n and mean ± standard deviation (SD) for continuous parameters, and frequency and percentage for categorical parameters).

Statistical analyses were performed for SEA, and HD ICS SEA, vs general asthma populations; $p < 0.05$ was considered statistically significant. Continuous variables were analyzed using t-test and categorical variables using Chi-square test. All analyses were conducted using SAS version 9.4. This was a descriptive epidemiologic study therefore no controlling for confounding, sample size or power/precision calculations were performed. Missing values were not imputed. Data cleaning methods were not required.

Ethics Approval and Consent to Participate

This observational study complied with the principles laid down by the 64th World Medical Assembly (Helsinki, 2013). The study was conducted in accordance with legal and regulatory requirements/guidelines, as well as with scientific purpose, value and rigor; and followed generally accepted research practices.

Informed consent was not required in this retrospective study using the VGHTC database since these anonymized data were approved for the use in observational research and the study did not involve the contact with patients. This study complied with all applicable laws regarding subject privacy. The study posed minimal privacy risk for patients and had been approved by the Institutional Review Board of VGHTC (IRB code: SF16245B).

Results

Baseline patient demographics and clinical characteristics

Of 9,455 patients with asthma diagnosis codes, 2,601/9,455 (27.5%) met the inclusion criteria; 162/2,601 (6.2%) met SEA criteria and among these, 72/162 patients (44.4%) had used HD ICS (**Figure 1**). Mean age was comparable between the populations, and most patients were aged ≥ 50 years. SEA and general asthma patients had comparable BMI scores, while HD ICS SEA patients had a significantly higher BMI compared with general asthma patients ($p < 0.05$). Most patients from all populations had total IgE levels of > 30 and < 1300 IU/mL (**Table 1**).

A significantly greater proportion of HD ICS SEA and SEA patients were female compared with general asthma patients (56.9% and 51.9%, respectively vs 40.8%; $p < 0.01$), had atopy and had more comorbidities; HD ICS SEA and SEA populations also included higher proportions of patients who were current or had ever been smokers. On the index date, BECs of ≥ 300 cells/μL were recorded for 58.0% of SEA patients vs 52.7% HD ICS SEA patients vs 14.7% general asthma patients (**Table 1**). Findings for the BEC subgroups of SEA patients are reported in **Appendix S2**.

Exacerbations

In the 12-month follow-up period, the mean number of exacerbations was significantly higher for HD ICS SEA and SEA vs general asthma patients: 1.5 ± 2.59 and 1.6 ± 3.32 vs 0.6 ± 2.02, respectively (**Table 2**).


Figure 1. Patient flow diagram
[a] asthma patients meeting criteria 1–3; [b] SEA patients meeting criteria 1–6; ICS, inhaled corticosteroids; SEA, severe eosinophilic asthma; VGHTC, Taichung Veterans General Hospital.

Proportions of SEA and HD ICS SEA patients experiencing 1–2, 3, or ≥ 4 exacerbations were at least 2-fold greater compared with general asthma patients ($p < 0.0001$; **Table 2**). Proportions of patients who experienced exacerbations requiring hospitalization or an ED visit were highest for HD ICS SEA patients, while those who used OCS was highest for the general asthma population (**Table 2**).

Utilization of respiratory medications

The respiratory medications coverage rate in the 12-month follow-up period was significantly higher for HD ICS SEA and SEA vs general asthma patients, with 2- to 3-fold greater use for many medication classes, including LAMA, SABA, theophylline and tiotropium (**Table 3**). Overall, a fixed-dose ICS + LABA combination was the most commonly used medication, and was used by all HD ICS SEA, 94.4% of SEA vs 57.6% of general asthma patients (**Table 3**).

In the SEA and HD ICS SEA populations, proportions of patients receiving omalizumab was low, but significantly greater than for general asthma patients (6.2% and 9.7% vs 2.3%, respectively). At least 2-fold more SEA and HD ICS SEA patients than general asthma patients used systemic corticosteroids (14.8% vs 16.7% vs 6.4%, respectively, **Table 3**).

When classified based on exacerbations and OCS use, the number of SEA patients with 6 months' continuous use of OCS was low across subpopulations (see **Appendix S2**).

Table 1. Baseline patient demographics and clinical characteristics

Items		General asthma n = 2439	HD-ICS SEA n = 72	SEA n = 162	SEA population by eosinophil level (cells/µL) n = 162				P value* vs General asthma	
					< 150 n = 29	150-300 n = 39	> 300-400 n = 35	> 400 n = 59	HD ICS SEA	SEA
Age (years), mean ± SD		61.9 ± 16.42	64.6 ± 17.97	62.9 ± 17.88	66.0 ± 16.53	60.4 ± 19.19	64.3 ± 15.42	62.2 ± 19.08	0.18	0.47
Age groups (years), n (%)	18 to < 30	101 (4.1)	3 (4.2)	7 (4.3)	0 (-.-)	4 (10.3)	0 (-.-)	3 (5.1)		
	30 to < 50	444 (18.2)	13 (18.1)	34 (21.0)	7 (24.1)	6 (15.4)	7 (20.0)	14 (23.7)	1.00	0.66
	50 to < 70	1021 (41.9)	27 (37.5)	62 (38.3)	10 (34.5)	18 (46.2)	13 (37.1)	21 (35.6)		
	≥ 70	873 (35.8)	29 (40.3)	59 (36.4)	12 (41.4)	11 (28.2)	15 (42.9)	21 (35.6)		
Gender, female, n (%)		995 (40.8)	41 (56.9)	84 (51.9)	11 (37.9)	22 (56.4)	17 (48.6)	34 (57.6)	0.006*	0.006*
BMI (kg/m²)	Missing	1209	7	30	4	4	6	16	0.05*	0.47
	Mean ± SD	25.0 ± 4.77	26.6 ± 6.53	25.3 ± 5.60	27.2 ± 8.28	25.7 ± 6.16	25.2 ± 4.18	24.0 ± 3.54		
Smoking status, n (%)	Missing	7	0	0	0	0	0	0		
	Non-smokers	2043 (84.0)	52 (72.2)	124 (76.5)	22 (75.9)	25 (64.1)	28 (80.0)	49 (83.1)	0.002*	0.03*
	Ex-smokers	252 (10.4)	17 (23.6)	27 (16.7)	5 (17.2)	8 (20.5)	6 (17.1)	8 (13.6)		
	Smokers	137 (5.6)	3 (4.2)	11 (6.8)	2 (6.9)	6 (15.4)	1 (2.9)	2 (3.4)		
Total IgE (IU/mL),	Missing	2135	52	127	23	31	26	47		
n (%)	≤ 30	69 (22.7)	2 (10.0)	5 (14.3)	2 (33.3)	1 (12.5)	1 (11.1)	1 (8.3)	0.41	0.25
	> 30 to < 1300	212 (69.7)	16 (80.0)	25 (71.4)	3 (50.0)	6 (75.0)	7 (77.8)	9 (75.0)		
	≥ 1300	23 (7.6)	2 (10.0)	5 (14.3)	1 (16.7)	1 (12.5)	1 (11.1)	2 (16.7)		
Eosinophil level	Missing	1163	0	0	0	0	0	0		
(cells/µL)	Mean ± SD, median (IQR)	167.3 ± 172.86, 120.0 (56.8–214.8)	475.5 ± 574.81, 310.2 (210.3–509.4)	467.5 ± 504.17, 326.4, (210.0–518.4)	78.0 ± 43.95, 81.9 (41.0–121.6)	236.6 ± 42.70, 241.2 (202.8– 277.2)	344.9 ± 30.64, 340.0 (319.3–377.4)	884.3 ± 636.74, 644.8 (500.5–1004.8)	< 0.001*	< 0.001*
Eosinophil level	Missing	1163	0	0	-	-	-	-		
(cells/µL), n (%)	< 100	534 (41.8)	12 (16.7)	18 (11.1)	-	-	-	-	< 0.001*	< 0.001*
	100 to < 150	246 (19.3)	3 (4.2)	11 (6.8)	-	-	-	-		
	150 to < 200	138 (10.8)	2 (2.8)	9 (5.6)	-	-	-	-		
	200 to < 250	105 (8.2)	8 (11.1)	13 (8.0)	-	-	-	-		
	250 to < 300	66 (5.2)	9 (12.5)	17 (10.5)	-	-	-	-		
	300 to < 400	71 (5.6)	15 (20.8)	35 (21.6)	-	-	-	-		
	≥ 400	116 (9.1)	23 (31.9)	59 (36.4)	-	-	-	-		

Table 1. (Continued)

| Items | | General asthma n = 2439 | HD-ICS SEA n = 72 | SEA n = 162 | SEA population by eosinophil level (cells/µL) n = 162 | | | | P value# vs General asthma | |
					< 150 n = 29	150-300 n = 39	> 300-400 n = 35	> 400 n = 59	HD ICS SEA	SEA
Comorbidities¥, n (%)	None	593 (24.3)	13 (18.1)	32 (19.8)	1 (3.4)	15 (38.5)	4 (11.4)	12 (20.3)		
	1–2	1505 (61.7)	34 (47.2)	86 (53.1)	15 (51.7)	18 (46.2)	20 (57.1)	33 (55.9)		
	3–5	317 (13.0)	24 (33.3)	40 (24.7)	11 (37.9)	5 (12.8)	10 (28.6)	14 (23.7)	< 0.001*	< 0.001*
	> 5	24 (1.0)	1 (1.4)	4 (2.5)	2 (6.9)	1 (2.6)	1 (2.9)	0 (–.–)		
Atopy, n (%)		209 (8.6)	12 (16.7)	22 (13.6)	2 (6.9)	6 (15.4)	6 (17.1)	8 (13.6)	0.03*	0.04*

¥ Comorbidities include nasal polyps, rhinitis allergic, rhinitis chronic, tachycardia, dysrhythmias, atrial fibrillation, cardiac dysrhythmias, myocardial infarction, angina pectoris, unstable angina, transient ischemic attack, other forms of chronic ischemic heart disease, cardiac failure congestive, atrioventricular block, bundle branch block right, conduction disorder, palpitations, pericardial effusion, ventricular extra-systoles, hypertension, pulmonary hypertension, cerebrovascular disorders, ischemic stroke, hemorrhagic stroke, pulmonary embolism, hypotension, and thrombophlebitis.
Between-group comparison by *t* test for continuous data and Chi-square test for categorical data. * Denotes statistical significance. BMI, body mass index; CI, confidence interval; HD ICS, high-dose inhaled corticosteroid; IgE, immunoglobulin E; IQR, interquartile range; SD, standard deviation; SEA, severe eosinophilic asthma

Table 2. Asthma exacerbations during the 12-month follow-up period

| Items | | General asthma n = 2439 | HD ICS SEA n = 72 | All SEA n = 162 | SEA population by eosinophil level (cells/µL) n = 162 | | | | P-value# vs General asthma | |
					< 150 n = 29	150-300 n = 39	> 300-400 n = 35	> 400 n = 59	HD ICS SEA	All SEA
Exacerbations (times/patient-year), mean ± SD, median (IQR)		0.6 ± 2.02, 0.0 (0.0–0.0)	1.5 ± 2.59, 0.0 (0.0–2.0)	1.6 ± 3.32, 0.0 (0.0–1.0)	1.6 ± 3.19, 0.0 (0.0–1.0)	1.5 ± 3.47, 0.0 (0.0–1.0)	1.2 ± 1.77, 0.0 (0.0–2.0)	1.9 ± 3.96, 1.0 (0.0–2.0)	0.006*	< 0.001*
Number of exacerbations	None	1974 (80.9)	38 (52.8)	85 (52.5)	18 (62.1)	21 (53.8)	18 (51.4)	28 (47.5)		
(times/year), n (%)	1–2	323 (13.2)	20 (27.8)	50 (30.9)	4 (13.8)	14 (35.9)	11 (31.4)	21 (35.6)	< 0.001*	< 0.001*
	3	33 (1.4)	4 (5.6)	6 (3.7)	2 (6.9)	1 (2.6)	2 (5.7)	1 (1.7)		
	≥ 4	109 (4.5)	10 (13.9)	21 (13.0)	5 (17.2)	3 (7.7)	4 (11.4)	9 (15.3)		
Led to ED, n (%)		245 (52.7)	20 (58.8)	42 (54.5)	6 (54.5)	6 (33.3)	10 (58.8)	20 (64.5)	0.49	0.76
Led to hospitalization, n (%)		217 (46.7)	19 (55.9)	36 (46.8)	5 (45.5)	12 (66.7)	10 (58.8)	9 (29.0)	0.30	0.99
Used OCS, n (%)		97 (20.9)	5 (14.7)	14 (18.2)	3 (27.3)	3 (16.7)	2 (11.8)	6 (19.4)	0.39	0.59
OCS dose (mg/day), mean ± SD, median (IQR)		11.4 ± 13.50, 7.2 (4.0–16.0)	17.8 ± 13.69, 17.7 (6.0–24.0)	11.2 ± 9.85, 8.0 (4.0–17.7)	4.9 ± 1.03, 4.6 (4.0–6.0)	16.4 ± 18.27, 8.0 (3.8–37.3)	13.5 ± 14.85, 13.5 (3.0–24.0)	11.0 ± 5.63, 9.2 (8.0–17.7)	0.30	0.96

Between-group comparison by *t* test for continuous data and Chi-square test for categorical data. * Denotes statistical significance. ED, emergency department; HD ICS, high-dose inhaled corticosteroid; IQR, interquartile range; OCS, oral corticosteroids, SEA, severe eosinophilic asthma; SD, standard deviation.

Table 3. Overall respiratory medication adherence and utilization during the 12-month follow-up period

| Items		General asthma n = 2439	HD-ICS SEA n = 72	SEA n = 162	SEA population by eosinophil level (cells/μL) n = 162				P value† vs General asthma	
					< 150 n = 29	150-300 n = 39	>300-400 n = 35	> 400 n = 59	HD ICS SEA	SEA
Adherence, PDC (%)	Overall, mean ± SD, median (IQR)	66.8 ± 36.17, 84.7 (32.3–100.0)	73.7 ± 31.66, 89.5 (53.8–100.0)	67.2 ± 34.13, 83.0 (40.0–99.7)	65.8 ± 34.63, 80.5 (38.4–95.9)	61.8 ± 36.57, 61.9 (27.7–100.0)	72.2 ± 34.21, 91.0 (46.3–100.0)	68.5 ± 32.59, 82.7 (46.8–99.7)	0.11	0.89
PDC level, n (%)	High (> 80)	988 (52.1)	44 (61.1)	83 (52.2)	15 (51.7)	18 (48.6)	20 (58.8)	30 (50.8)		
	Medium (50 to < 80)	256 (13.5)	11 (15.3)	24 (15.1)	4 (13.8)	6 (16.2)	3 (8.8)	11 (18.6)		
	Low (30 to < 50)	207 (10.9)	6 (8.3)	20 (12.6)	4 (13.8)	3 (8.1)	6 (17.6)	7 (11.9)	0.30	0.71
	Very low (< 30)	445 (23.5)	11 (15.3)	32 (20.1)	6 (20.7)	10 (27.0)	5 (14.7)	11 (18.6)		
	Missing†	543	0	3	0	2	1	0		
Medications, n (%)										
LAMA		182 (7.5)	14 (19.4)	21 (13.0)	4 (13.8)	7 (17.9)	4 (11.4)	6 (10.2)	< 0.001*	0.01*
LABA		56 (2.3)	2 (2.8)	6 (3.7)	0 (–,–)	1 (2.6)	1 (2.9)	4 (6.8)	1.00	0.38
ICS		219 (9.0)	6 (8.3)	13 (8.0)	0 (–,–)	6 (15.4)	4 (11.4)	3 (5.1)	0.85	0.68
SAMA		0 (–,–)	0 (–,–)	0 (–,–)	0 (–,–)	0 (–,–)	0 (–,–)	0 (–,–)	NA	NA
SABA		719 (29.5)	38 (52.8)	77 (47.5)	19 (65.5)	16 (41.0)	17 (48.6)	25 (42.4)	< 0.001*	< 0.001*
Theophylline		349 (14.3)	32 (44.4)	52 (32.1)	12 (41.4)	13 (33.3)	9 (25.7)	18 (30.5)	< 0.001*	< 0.001*
LTRA		621 (25.5)	22 (30.6)	51 (31.5)	8 (27.6)	7 (17.9)	16 (45.7)	20 (33.9)	0.33	0.09
Systemic corticosteroids		155 (6.4)	12 (16.7)	24 (14.8)	6 (20.7)	5 (12.8)	4 (11.4)	9 (15.3)	0.001*	< 0.001*
Systemic β agonists		114 (4.7)	6 (8.3)	13 (8.0)	3 (10.3)	3 (7.7)	3 (8.6)	4 (6.8)	0.25	0.06
Omalizumab (Xolair)		56 (2.3)	7 (9.7)	10 (6.2)	1 (3.4)	1 (2.6)	3 (8.6)	5 (8.5)	< 0.001*	0.005*
Tiotropium		167 (6.8)	12 (16.7)	19 (11.7)	3 (10.3)	7 (17.9)	3 (8.6)	6 (10.2)	0.001*	0.02*
ICS + LABA (free-dose)		11 (0.5)	0 (–,–)	1 (0.6)	0 (–,–)	0 (–,–)	0 (–,–)	1 (1.7)	0.57	1.00
ICS + Theophylline (free-dose)		25 (1.0)	3 (4.2)	3 (1.9)	0 (–,–)	1 (2.6)	0 (–,–)	2 (3.4)	0.05	0.55
ICS + LTRA (free-dose)		59 (2.4)	2 (2.8)	5 (3.1)	0 (–,–)	1 (2.6)	2 (5.7)	2 (3.4)	1.00	0.79
LABA + LAMA (fixed-dose)		9 (0.4)	0 (–,–)	1 (0.6)	0 (–,–)	0 (–,–)	0 (–,–)	1 (1.7)	0.61	1.00
SABA + SAMA (fixed-dose)		285 (11.7)	31 (43.1)	46 (28.4)	10 (34.5)	14 (35.9)	8 (22.9)	14 (23.7)	< 0.001*	< 0.001*
ICS + LABA (fixed-dose)		1404 (57.6)	72 (100)	153 (94.4)	29 (100)	36 (92.3)	31 (88.6)	57 (96.6)	< 0.001*	< 0.001*

* Between-group comparison by Chi-square test. * Denotes statistical significance. †Indicates non-users of medication. ICS, inhaled corticosteroid; HD ICS, high-dose inhaled corticosteroids; IQR, interquartile range; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; LTRA, leukotriene receptor antagonist; NA, not applicable; SABA, short-acting β2-agonists; SAMA, short-acting muscarinic antagonists; SEA, severe eosinophilic asthma.

**Table 4. Healthcare resource use in the 12-month follow-up period**

Items (times/patient-year)	General asthma (n = 1000#)	HD ICS SEA (n = 1000#)	All SEA (n = 1000#)	SEA population by eosinophil level (cells/µL) (n = 1000#)				P-value vs General asthma	
				< 150	150-300	> 300-400	> 400	HD ICS SEA	All SEA
OPD	4.2 ± 0.11	4.5 ± 0.76	4.7 ± 0.48	5.0 ± 1.38	2.6 ± 0.65	5.0 ± 0.93	5.9 ± 0.91	0.63	0.20
ED	0.0 ± 0.01	0.2 ± 0.07	0.2 ± 0.08	0.1 ± 0.08	0.3 ± 0.29	0.1 ± 0.04	0.2 ± 0.09	0.005*	0.001*
Hospitalization	0.0 ± 0.00	0.1 ± 0.03	0.0 ± 0.01	0.0 ± 0.03	0.1 ± 0.04	0.0 ± 0.03	0.0 ± 0.02	< 0.001*	0.003*
Length of stay (all-cause, days)	2.8 ± 0.20	13.7 ± 2.23	9.2 ± 1.30	10.8 ± 3.20	12.8 ± 2.78	8.1 ± 2.65	6.7 ± 1.90	0.001*	< 0.001*
Length of stay (asthma-related, days)	0.1 ± 0.02	0.6 ± 0.33	0.3 ± 0.14	0.4 ± 0.38	0.2 ± 0.11	0.5 ± 0.53	0.1 ± 0.14	0.002*	0.03*
ICU	0.0 ± 0.00	0.0 ± 0.02	0.0 ± 0.01	0.0 ± 0.00	0.0 ± 0.00	0.1 ± 0.04	0.0 ± 0.00	0.008*	0.03*

Frequency was estimated by bootstrapping method using 1000 replicates. * Denotes statistical significance. ED, emergency department; ICU, intensive care unit; HRU, healthcare resource utilization; OPD, outpatient department; SEA, severe eosinophilic asthma; SD, standard deviation.

Figure 2. Asthma-related and all-cause medical costs in the 12-month follow-up period

A. Asthma-related costs in HD ICS SEA, SEA and general asthma populations

B. Asthma-related costs in SEA population stratified by eosinophil level

C. All-cause medical costs in HD ICS SEA, SEA and general asthma populations

D. All-cause medical costs in SEA population stratified by eosinophil level

Costs were estimated by bootstrapping method using 1000 replicates. * p value < 0.05, ** < 0.01 and *** < 0.001. ED, emergency department; HD ICS, high-dose inhaled corticosteroids; OPD, outpatient department; SD, standard deviation; SEA, severe eosinophilic asthma; USD, United States Dollars

Adherence to respiratory medications

Mean overall PDC, for aggregated respiratory medications, and for most specific medications, was comparable between SEA and general asthma patients and higher for HD ICS SEA patients in the 12-month follow up period (**Table 3**). The greatest proportion of patients with a PDC level ≥ 80%, was observed in HD ICS SEA patients (HD ICS SEA vs SEA vs general asthma: 61.1% vs 52.2% vs 52.1%; **Table 3**).

Healthcare resource use and costs

There were significantly more asthma-related ED visits, but not OPD visits, for both SEA and HD ICS SEA populations vs the general asthma population in the 12-month follow up period (*p* < 0.01). SEA and HD ICS SEA patients also had significantly higher asthma-related hospitalizations and ICU admissions. Asthma-related length of stay, and all-cause length of stay was significantly longer by at least 3-fold for these patients vs general asthma patients (*p* < 0.05; **Table 4**).

Asthma-related and all-cause costs

The HD ICS SEA and SEA populations incurred significantly greater asthma-related costs for each healthcare category vs the general asthma population; total asthma-related costs were also higher by at least 2.5-fold for these patient populations. OPD costs were the primary driver of total costs (**Figure 2A**). Significantly greater all-cause costs (2–3 fold) across all healthcare categories were also incurred by HD ICS SEA and SEA populations vs the general asthma population; total all-cause costs were $8812.6 and $6517.8 vs $2782.8, respectively. OPD costs were the primary driver of total costs (**Figure 2C**).

There was variation in HCRU and costs between the BEC subgroups of SEA patients (**Appendix S2**).

Discussion

Real-world evidence describing patients with SEA and their associated HCRU is limited in Asia. We found 6.2% of patients met predefined criteria for SEA; 44.4% of these had used HD ICS therapy. SEA and HD ICS SEA patients experienced a higher number of exacerbations than general asthma patients despite greater medication usage, and accounted for higher asthma-related and all-cause HCRU and costs.

HD ICS SEA and SEA patients in Taiwan were similar in age to general asthma patients and more likely to be female, contrasting with a UK SEA population who were more likely to be older than the main study population and for which similar proportions of female patients were found.[17] In the SA Research Program however, female patients were also more likely to have SEA.[18] Consistent with the UK study, Taiwanese SEA and HD ICS SEA patients had more comorbidities and atopy.[17]

Epidemiological and HCRU data on SEA patients is available from Western studies. Kerkhof et al (2018) reported that 10% of UK patients with active asthma were prescribed HD ICS/LABA - greater than the proportion we identified. Patients with SEA (defined similarly to our study as ≥ 2 exacerbations in the baseline year and a BEC of ≥ 0.3 × 10⁹/L at index date; n = 2940, 0.8%) also accounted for 2.5–7.6-times

greater mean HCRU and direct asthma-related costs for each HCRU-related category vs the main active-asthma population. In the US, higher asthma-related costs have also been associated with elevated eosinophil levels.[19] In our study we found asthma-related costs, for all HCRU categories, were substantially higher (over 2-fold) for the HD ICS SEA and SEA patient populations, vs the general asthma population, but we did not see trends in increasing HCRU and associated costs with increasing eosinophil level within the SEA population, in contrast to other data.[17] A comparison of absolute asthma-related costs is difficult to make between countries due to socioeconomic differences and differences in healthcare systems. However, regarding relative costs, a systematic literature review of economic burden of asthma in 68 studies found hospitalization and medication costs were the most important drivers of direct costs,[20] while we found OPD costs to be the main driver. In our study, there were limited episodes of asthma-related hospitalization occurring during the 12-month follow-up period (SEA patients had 0.3 ± 0.14 days/patient-year of hospitalization due to asthma, as shown in **Table 4**). This is in-line with our expectation as patients treated at tertiary medical centres are given specialized and intensive care to keep symptoms under control; this was reflected in the greater utilization of OPD services (4.7 ± 0.48 times/patient-year for SEA patients) which resulted in greater healthcare resource use on OPD visits and medication.

Respiratory medication coverage rates were higher for SEA vs general asthma patients by 2- to 3-fold; however, adherence to overall respiratory medications was comparable (~67%), and higher in HD ICS SEA patients (73.7%); these values are considered high based on studies examining the compliance rate of asthma patients (55%)[15] and the adherence rate of patients with SA (28–67%).[21] Of note, our overall medication adherence for SEA and HD ICS SEA patients based on PDC ≥ 80% was broadly similar to that demonstrated previously for long-term oral and inhaled controller medication in a patient population with SA (58.3%).[22] Despite high medication coverage rates, we found approximately half of SEA and HD ICS SEA patients continued to experience exacerbations. Considering the high overall medication adherence results, the likelihood that the asthma of SEA or HD ICS SEA patients in our study would be categorized as difficult-to-treat rather than refractory[7] due to poor adherence is therefore low. We also assessed comorbidities and modifiable risk factors in the study and found that this was higher in SEA vs. general asthma population. Though SEA patients were more frequently prescribed with SABA vs. general asthma patients (**Table 3**), the rate of PDC was not different between SEA and general asthma patients (**Appendix S2**). The persistence of exacerbations in these patient populations is therefore more likely indicative of suboptimal disease control with current treatments. As per GINA guidelines for the diagnosis and management of asthma, severe asthma is asthma that is poorly controlled despite being managed with GINA Step 4–5 treatment, good adherence and good inhaler techniques.[23] As patients in our study fulfilled these criteria, and the majority of the patients had access to inhaler training, we believed most of the patients we recruited had severe asthma rather than difficult-to-treat asthma.

We found few SEA patients were using omalizumab. A retrospective, population-based cohort study using Taiwan National Health Insurance data also reported low coverage of omalizumab (0.4% SAA patients in 2011), despite associated reductions in number of asthma medications, exacerbations and ED visits.[24] In Korean SA patients, omalizumab was found to be used in just 1.8%, although this only represents private use.[25] Low biologic utilization may be due to healthcare reimbursement factors,[25] associated costs that may hinder prescription of biologics by physicians, reservation of omalizumab for patients specifically with SAA, or to patients' treatment with multiple non-biologic medications and/or non-evident clinical benefits over contemporary maintenance inhaler treatments.[26]

This is the first study in Taiwan assessing epidemiology and burden of SEA and provides needed real-world, and ethnic data on SEA in an adult, Chinese population. Although clinical databases can be associated with data quality issues and missing variables, the use of the VGHTC research-ready database[27] may minimize this as it contains a combination of EMR and claims data. Our study has some limitations. Patients with COPD were not excluded, limiting homogeneity of the study population, and patient numbers in the subgroups of SEA patients stratified by BEC were small, limiting comparisons between groups. This research was conducted in a single, though large medical center in Central Taiwan, which could limit external generalizability. However, cost data are expected to be broadly representative of other centers in Taiwan, as prescription patterns and quality of care should be standardized between centers. A further limitation is immortal-time bias, as data for patients who may have died within 12 months after the index date would have been excluded from the study. Lastly, because data from the VGHTC EMR database were not originally collected to answer research questions, misclassification bias can occur.

Conclusion

Our results indicate an unmet need for effective treatments for patients classified with SEA in Taiwan; these patients account for substantially greater asthma-related HCRU and all-cause medical costs than general asthma patients.

Consent for Publication

Not applicable

Availability of Data and Materials

GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to www.clinicalstudydatarequest.com. To access data for other types of GSK sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.

Competing Interests

SS and Y-FH are employees of and holds stocks with GlaxoSmithKline; L-WT and T-ML reports no competing interests; Y-HC: reports grant payment and consulting fees or honoraria from GlaxoSmithKline.

Author Contributions

Y-HC had full review access to the database population used to create the study population and SS, Y-FH, L-WT and T-ML were provided with the full clinical study report for review as part of this analysis. SS, Y-FH, L-WT, T-ML and Y-HC contributed to the conception, design, execution or analysis, and interpretation of these data. All authors approved the final version to be published after critically revising the manuscript/publication for important intellectual content.

References

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.
2. Global Initiative for Asthma [Internet]. Fontana: GINA; c2020 [cited 2020 Mar 2]. Global Strategy for Asthma Management and Prevention, 2018; [about 1 screen]. Available from: https://www.ginasthma.org.
3. Calhoun WJ, Haselkorn T, Mink DR, Miller DP, Dorenbaum A, Zeiger RS. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract. 2014;2(2):193-200.
4. Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, et al. The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults. Int Arch Allergy Immunol. 2013;160(1): 93-101.
5. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE, Group TS. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62(2):126-33.
6. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012;129(5):1229-35.
7. Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, et al. Asthma That Is Not Well-Controlled Is Associated with Increased Healthcare Utilization and Decreased Quality of Life. J Asthma. 2011;48(2):126-32.
8. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308-21.
9. Omachi TA, Iribarren C, Sarkar U, Tolstykh I, Yelin EH, Katz PP, et al. Risk factors for death in adults with severe asthma. Ann Allergy Asthma Immunol. 2008;101(2):130-6.
10. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115-20.
11. Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44(9):1137-45.
12. Albers FC, Mullerova H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):152-60.
13. Global Initiative for Asthma [Internet]. Fontana: GINA; c2020 [cited 2020 Mar 2]. Global Strategy for Asthma Management and Prevention, 2015. Available from:https://www.ginasthma.org.

14. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Curr Drug Targets. 2018;19(16):1882-96.

15. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8): 1296-310.

16. Pharmacy Quality Alliance [Internet]. Alexandria (VA); c2018 [cited 2020 Mar 2]. PQA Adherence Measures, 2018; [about 1 screen]. Available from:https://www.pqaalliance.org/adherence-measures.

17. Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116-24.

18. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4): 315-23.

19. Casciano J, Krishnan J, Dotiwala Z, Li C, Sun SX. Clinical and Economic Burden of Elevated Blood Eosinophils in Patients With and Without Uncontrolled Asthma. J Manag Care Spec Pharm. 2017;23(1):85-91.

20. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.

21. Boutopoulou B, Koumpagioti D, Matziou V, Priftis KN, Douros K. Interventions on Adherence to Treatment in Children With Severe Asthma: A Systematic Review. Front Pediatr. 2018;6:232.

22. Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, et al. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. J Manag Care Spec Pharm. 2016;22(7):848-61.

23. Global Initiative for Asthma [Internet]. Fontana: GINA; c2020 [cited 2020 Jun 22]. Diffucult-to-Treat & Severe Asthma in adolescent and adult patients Diagnosis and Management and Prevention, 2018. Available from:https://www.ginasthma.org.

24. Chen HC, Huang CD, Chang E, Kuo HP. Efficacy of omalizumab (Xolair(R)) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med. 2016;16:3.

25. Kim MH, Kim SH, Park SY, Ban GY, Kim JH, Jung JW, et al. Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry. Allergy Asthma Immunol Res. 2019; 11(1):43-54.

26. Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, et al. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann Allergy Asthma Immunol. 2018;120(1):59-65 e2.

27. Yang U-C, Hsiao T-H, Lin C-H, Lee W-J, Y.-S. L, Fann Y, C. Integrative LHS for precision medicine research: A shared NIH and Taiwan CIMS experience. Learn Health Syst. 2018;e10071.

Appendix S1
Supplementary Methods
Taichung Veterans General Hospital (VGHTC)

The VGHTC EMR database captures patients' demographic, prescription, hospital admissions and referrals information, and prescription- and patient-level costs (inclusive of self-pay and reimbursement claims to the National Health Insurance) on all patients seen in the VGHTC healthcare system since 2009. The VGHTC network includes four hospitals (VGHTC, Chiayi Branch, Puli Branch, Wanqiao branch) that provide a standardized quality of care across sites in different geographical locations spanning the entire district in central Taiwan. The EMR data from the hospitals reside on a shared database - the Clinical Information Research & Development Center (CIDC) shared database platform.

Patient Inclusion Criteria
ICD-9 codes of asthma and comorbidities of interest

The International Classification of Diseases (ICD) codes used in the identification of asthma and comorbidities of interest are listed in the table below.

Table S1. ICD-9 codes of asthma and comorbidities of interest

Comorbidities of Interest	ICD-9 codes
Asthma	493.00, 493.01, 493.02, 493.10, 493.11, 493.12, 493.90, 493.91 (ICD-10 codes: J45, J46)
Nasal polyps	471.0, 471.9
Rhinitis allergic	477, 477.0, 477.1, 477.2, 477.8, 477.9
Rhinitis chronic	472, 472.0, 472.1, 472.2
Cardiac Disorders	
Tachycardia, dysrhythmias	427.0, 427.1, 427.2, 427.6 (427.60, 427.61, 427.69)
Atrial fibrillation	427.3 (427.31, 427.32)
Cardiac dysrhythmias (Other specified and unspecified)—includes bradycardia	427.8 (427.81, 427.89), 427.9
Myocardial infarction	410 (410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11, 410.12, 410.2, 410.20, 410.21, 410.22, 410.3, 410.30, 410.31, 410.32, 410.4, 410.40, 410.41, 410.42, 410.5, 410.50, 410.51, 410.52, 410.6, 410.60, 410.61, 410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81, 410.82, 410.9, 410.90, 410.91, 410.92) 411 (411.0, 411.1, 411.8, 411.81, 411.89)
Angina pectoris	413 (413.0, 413.1, 413.9)
Unstable angina	411.1
Transient ischemic attack	V12.54
Other forms of chronic ischemic heart disease	414 (414.0, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06, 414.07, 414.1, 414.10, 414.11, 414.12, 414.19, 414.8, 414.9)
Cardiac failure congestive (congestive heart failure)	428 (428.0, 428.1 428.2, 428.20, 428.21, 428.22, 428.23,428.3, 428.30, 428.31, 428.32, 428.33, 428.4, 428.40, 428.41, 428.42, 428.43,428.9
Atrioventricular block	426.1 (426.10, 426.11, 426.12, 426.13)
Bundle branch block right	426.4
Conduction disorder (excludes atrioventricular block and bundle branch block right)	426 (426.0, 426.2, 426.3, 426.5, 426.50, 426.51, 426.52, 426.53, 426.54, 426.6, 426.7, 426.8, 426.81, 426.82, 426.89, 426.9)
Palpitations	785.1
Pericardial effusion	420
Ventricular extra-systoles	427.60, 427.69

Table S1. (Continued)

Comorbidities of Interest	ICD-9 codes
Hypertension	401 (401.0, 401.1, 401.9) 402 (402.0, 402.00, 402.01, 402.1, 402.10, 402.11, 402.9, 402.90, 402.91) 403 (403.0, 403.00, 403.01, 403.1, 403.10, 403.11, 403.9, 403.90, 403.91) 404 (404.0, 404.00, 404.01, 404.02, 404.03, 404.1, 404.10, 404.11, 404.12, 404.13, 404.9, 404.90, 404.91, 404.92, 404.93) 405 (405.0, 405.01, 405.09, 405.1, 405.11, 405.19, 405.9, 405.91, 405.99)
Pulmonary hypertension	416.0, 416.8
Cerebrovascular disorders (that is not stroke)	780.3, 780.31, 780.32, 780.39 (Seizures/ convulsions (non-epileptic) 436, 437, 438
Ischemic stroke	433 (433.0, 433.00, 433.01,433.1, 433.10, 433.11,433.2, 433.20, 433.21,433.3, 433.30, 433.31,433.8, 433.80, 433.81,433.9, 433.90, 433.91) 434 (434.0, 434.00, 434.01, 434.1, 434.10, 434.11, 434.9, 434.90, 434.91) 437.1
Hemorrhagic stroke	430, 431, 432, 432.0, 432.1, 432.9
Pulmonary embolism	Pulmonary embolism: 415.1, 415.19 Deep vein thrombosis (upper and lower extremities): 451.1 (451.11, 451.19), 451.2, 451.81, 451.83, 451.84, 453.1, 453.2, 453.4 (453.40, 453.41, 453.42), 453.8, 453.9 Portal vein thrombosis: 452 Other thromboembolic events: 362.35, 362.36, 437.6, 451.0, 451.82, 451.89, 451.9, 453.0, 453.2, 453.3
Hypotension	458 (458.0, 458.1, 458.2, 458.21, 458.29, 458.8, 458.9)
Thrombophlebitis	999.2

SEA patients

Criteria for GINA step 4 or 5 treatment were as follows: Step 4 - Add on tiotropium or a leukotriene receptor antagonist (LTRA) and/or sustained release theophylline to any of the GINA Step 3 treatments ([a] low-dose ICS plus LABA in a single device, [b] low-dose ICS plus LABA in multiple devices, [c] medium- or HD ICS, [d] low-dose ICS plus LTRA, or [e] low-dose ICS plus sustained-release theophylline) or combinations (to be considered as a treatment combination each medicine must have been prescribed within a 30-day window, the rule on medication combinations did not apply where ICS and LABA were administered in one inhaler), or were given medium- or high-dose (HD) ICS plus LABA in either a single device or in multiple devices; Step 5 - Patients who had also been given systemic steroids (i.e., oral corticosteroids [OCS]) or anti-IgE treatment (e.g., omalizumab [Xolair]) in addition to the GINA Step 4 treatment combinations.

Exacerbations were defined as use of OCS burst for asthma symptoms, asthma-related emergency department (ED) visit, or hospitalization.

HD ICS patients

An additional subgroup of patients, who had received HD ICS, was also extracted and analyzed, as in clinical practice, these patients may be considered for treatment with biologics (according to Step 5 GINA 2015: OCS or anti-IgE treatment in addition to Step 4 treatment) if they have maximized their choices of combination therapies and doses and have persistent symptoms despite optimized treatment with high dose controller medications and treatment of modifiable risk factors).

SEA Subpopulations

Patients with SEA were classified into the following four subpopulations to better characterise the patients eligible for treatment with biologics.

Table S2. Classification criteria for SEA subpopulations

Population 1	Population 2	Population 3	Population 4
At least 1 laboratory result with a BEC ≥ 300 cells/µL captured in 12 months prior to index date			
OR ≥ 150 cells/µL measured on index date			
A history of ≥ 2 exacerbations in the 12 months prior to index date OR Continuous OCS (5 mg per day) use for 6 months prior to index date	A history of ≥ 2 exacerbations in the 12 months prior to index date OR Continuous OCS (5 mg per day) use for 6 months prior to index date	A history of ≥ 4 exacerbations in the 12 months prior to index date OR Continuous OCS (5 mg per day) use for 6 months prior to index date	A history of ≥ 4 exacerbations in the 12 months prior to index date, with ≥ 1 exacerbation recorded as ED or hospitalization AND Continuous OCS (5 mg per day) use for 6 months prior to index date

Continuous OCS use was defined as follows: OCS1: A sequence of prednisolone claims that occurred ≤ 7 days between prescriptions (based on the prescription pattern in the local context – the clinic revisit interval is usually 7 days apart) OR OCS2: In the observational period, those with total prednisolone prescription ≥ 900 mg within 180 days post index (time varying covariates were ignored and the total prescribed dose of prednisolone of 5 mg/day for 180 days [≥ 900 mg] were counted) OR OCS3: Included OCS1 and OCS2.
Exacerbations were defined as above (see Patient Inclusion Criteria, SEA Patients).

The proportion of patients in each subpopulation was assessed for those with: 6-months continuous OCS use, BEC ≥ 150 cells/μL measured on index date, BEC ≥ 300 cells/μL captured in the 12 months prior to index date and number of exacerbations (2+/3+/4+/5+).

Demographics and clinical characteristics

Age, gender, body-mass index (BMI), smoking status, comorbidities, atopy status (scored 'Yes' if total IgE > 100 IU/mL or any of allergen-specific IgE > 0.35 KU/mL or if any multiple allergen-specific IgE screen was positive),[1,2] total IgE and BEC were described. BEC were described as the mean value over the 12-month follow-up period.

Exacerbations

An asthma-related ED visit was any record for an ED visit related to an asthma diagnosis code. An asthma-related hospital admission was any asthma-related referral or hospitalization with a discharge diagnosis of asthma. OCS-defined exacerbations were any OCS prescription with an asthma medical code recorded within ±2 weeks. Systemic steroids administered via injections were not included in the ascertainment of OCS-defined exacerbations as intravenous steroids were captured via hospitalization-related exacerbations.

Medication Use

Medication records in the database were encoded according to National Health Insurance drug codes. Asthma medications analysed in this study included: long-acting muscarinic agonists (LAMA), LABA, ICS, short-acting β2-agonists (SABA), theophylline, LTRA, systemic corticosteroids, systemic β agonists, omalizumab (Xolair), tiotropium, ICS+LABA (free-dose), ICS+theophylline (free-dose), ICS+LTRA (free-dose), LABA+LAMA (fixed-dose), SABA+short-acting muscarinic antagonists (SAMA) (fixed-dose), and ICS+LABA (fixed-dose).

Medication adherence

Assessment of medication adherence using proportion of days covered (PDC) started with the first claim for controller therapy; PDC was calculated as the ratio of medication covered days to duration of the medication treatment period (number of days).

OCS average daily dose

For multiple OCS claims to be considered part of the same episode, they must have had the same strength/dose; otherwise, OCS claims were considered as independent OCS episodes. This applied to OCS claims that occurred on the same date as well as those that occurred during a prior OCS treatment period. The average daily dose of OCS was calculated using prednisone equivalent doses.

All-cause and asthma-related healthcare costs

For asthma-related costs, all healthcare use encompassed medical claims with an asthma diagnosis in the primary position. All-cause costs were those irrespective of asthma diagnosis. For each category, total cost, and medication costs were reported. Total cost was the sum of all medical fees; medication costs included drug costs and any administration/infusion fees submitted on the same medical claim. The following healthcare costs were presented in this study for the 12-month follow-up period: 1) cost of hospitalization, 2) cost of OPD visits, and 3) cost of ED visits. Costs were standardized to the most recent year of data availability in Taiwan.

Bootstrapping procedure

The following algorithm was used in the bootstrapping method for cost calculation:

1. A sample of n patients (the same number as the study population) was drawn with replacement from the study population and the cost difference was calculated based on this sample using the linear model.
2. The sampling (i.e., step 1) was repeated and the cost difference calculated between exposure groups × times. In this study, 999 replications were used to carry out hypothesis testing.
3. The 999 + 1 (the original sample estimate) cost difference estimates were ordered from the lowest to the highest observed values.
4. The 95% CI was identified based on the 2.5 and 97.5 percentiles of the ranked values. The *p*-value was calculated from the observed empirical distribution.

Appendix S2
Supplementary Results: BEC Subgroups
Baseline patient demographics and clinical characteristics

Patient numbers for the various pre-specified BEC subgroups were small (n = 29–59 for the < 150 cells/μL cut-off and > 400 cells/μL cut-off groups, respectively), limiting the comparison of results between groups. However, the results for these subgroups were generally similar to the HD ICS SEA or overall SEA populations. The < 150 cells/μL subgroup was oldest, had fewest female patients, highest BMI, lowest atopy and the greatest patient proportion with IgE ≤ 30 IU/mL (**Table 1**).

Exacerbations

All eosinophil level subgroups of the SEA population had higher mean exacerbations (ranging from 1.2 ± 1.77 in the > 300–400 cells/μL group to 1.9 ± 3.96 in the > 400 cells/μL group) compared with the general asthma population. Numerically greater proportions of patients in each eosinophil-level subgroup of the SEA population experienced each category of exacerbations vs the general asthma patients. Number of ED visits or hospitalizations following exacerbations were generally similar to that for the SEA and HD ICS patients, although there was some variation between groups (**Table 2**).

Healthcare resource use and costs

There was variation in asthma-related HCRU in the different eosinophil subgroups but it was generally similar to that of the SEA or HD ICS SEA populations and greater than the general asthma population (**Table 4**).

Asthma-related and all-cause costs

Each of the eosinophil-level subgroups in the SEA incurred higher asthma-related costs vs general asthma patients; this result was most pronounced for the lowest and highest subgroups for OPD costs, medication costs, and total costs (**Figure 2B**). There was variation in all-cause costs between the different eosinophil subgroups for all healthcare categories; all subgroups incurred greater costs for all categories vs the general asthma population and the greatest all-cause costs for all healthcare categories except hospitalization costs were incurred by the 150–300 cells/µL subgroup (**Figure 3B**).

Use of SABA in SEA and general asthma patients

The rate of PDC were comparable between SEA and general asthma patients.

Table S3. PDC of SABA in SEA and general asthma patients

	General asthma (N = 2439)	All SEA (N = 162)	*P*-value
PDC (%), mean ± SD	33.7 ± 32.75	28.5 ± 32.64	0.18

Figure S1. Study Timeline

INDEX DATE: First asthma diagnosis after July 1st, 2014

12 months before index: July 1st, 2013

12 months after index: June 30th, 2016

Baseline period   Follow-up period

Supplementary Results: SEA subpopulations classified based on exacerbations and OCS use

Table S4. Clinical characteristics and OCS utilisation in SEA subpopulations at 3 months and 6 months during the follow-up period

OCS1	Population 1		Population 2		Population 3		Population 4	
	3 M N = 80	6 M N = 80	3 M N = 70	6 M N = 70	3 M N = 43	6 M N = 43	3 M N = 1	6 M N = 0
6 months continuous OCS	5 (6.3)	3 (3.8)	4 (5.7)	2 (2.9)	4 (9.3)	2 (4.7)	1 (100.0)	0 (0.0)
BEC ≥ 150 cells/µL (index date)	20 (25.0)	20 (25.0)	10 (14.3)	10 (14.3)	7 (16.3)	7 (16.3)	0 (0.0)	0 (0.0)
BEC ≥ 300 cells/µL (past 12 months)	70 (87.5)	70 (87.5)	70 (100.0)	70 (100.0)	43 (100.0)	43 (100.0)	1 (100.0)	0 (0.0)
No exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
1 exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
2 exacerbation	19 (23.8)	19 (23.8)	16 (22.9)	16 (22.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
3 exacerbation	13 (16.3)	13 (16.3)	11 (15.7)	11 (15.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
4 exacerbation	10 (12.5)	10 (12.5)	10 (14.3)	10 (14.3)	10 (23.3)	10 (23.3)	0 (0.0)	0 (0.0)
≥ 5 exacerbation	38 (47.5)	38 (47.5)	33 (47.1)	33 (47.1)	33 (76.7)	33 (76.7)	1 (100.0)	0 (0.0)
OCS2	3 M N = 83	6 M N = 83	3 M N = 73	6 M N = 73	3 M N = 47	6 M N = 47	3 M N = 2	6 M N = 0
6 months continuous OCS	5 (6.0)	3 (3.6)	4 (5.5)	2 (2.7)	4 (8.5)	2 (4.3)	1 (50.0)	0 (0.0)
BEC ≥ 150 cells/µL (index date)	20 (24.1)	20 (24.1)	10 (13.7)	10 (13.7)	8 (17.0)	8 (17.0)	0 (0.0)	0 (0.0)
BEC ≥ 300 cells/µL (past 12 months)	73 (88.0)	73 (88.0)	73 (100.0)	73 (100.0)	47 (100.0)	47 (100.0)	2 (100.0)	2 (100.0)
No exacerbation	3 (3.6)	3 (3.6)	3 (4.1)	3 (4.1)	3 (6.4)	3 (6.4)	0 (0.0)	0 (0.0)
1 exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
2 exacerbation	19 (22.9)	19 (22.9)	16 (21.9)	16 (21.9)	1 (2.1)	1 (2.1)	0 (0.0)	0 (0.0)
3 exacerbation	13 (15.7)	13 (15.7)	11 (15.1)	11 (15.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
4 exacerbation	10 (12.0)	10 (12.0)	10 (13.7)	10 (13.7)	10 (21.3)	10 (21.3)	0 (0.0)	0 (0.0)
≥ 5 exacerbation	38 (45.8)	38 (45.8)	33 (45.2)	33 (45.2)	33 (70.2)	33 (70.2)	2 (100.0)	2 (100.0)

Table S4. (Continued)

OCS3	Population 1		Population 2		Population 3		Population 4	
	3 M N = 80	6 M N = 80	3 M N = 70	6 M N = 70	3 M N = 43	6 M N = 43	3 M N = 1	6 M N = 0
6 months continuous OCS	5 (6.3)	3 (3.8)	4 (5.7)	2 (2.9)	4 (9.3)	2 (4.7)	1 (100.0)	0 (0.0)
BEC ≥ 150 cells/µL (index date)	20 (25.0)	20 (25.0)	10 (14.3)	10 (14.3)	7 (16.3)	7 (16.3)	0 (0.0)	0 (0.0)
BEC ≥ 300 cells/µL (past 12 months)	70 (87.5)	70 (87.5)	70 (100)	70 (100)	43 (100.0)	43 (100.0)	1 (100.0)	0 (0.0)
No exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
1 exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
2 exacerbation	19 (23.8)	19 (23.8)	16 (22.9)	16 (22.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
3 exacerbation	13 (16.3)	13 (16.3)	11 (15.7)	11 (15.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
4 exacerbation	10 (12.5)	10 (12.5)	10 (14.3)	10 (14.3)	10 (23.3)	10 (23.3)	0 (0.0)	0 (0.0)
≥ 5 exacerbation	38 (47.5)	38 (47.5)	33 (47.1)	33 (47.1)	33 (76.7)	33 (76.7)	1 (100.0)	0 (0.0)

BEC, blood eosinophil count; ED, emergency department; OCS, oral corticosteroid; SEA, severe eosinophilic asthma.

1. Chang ML, Cui C, Liu YH, Pei LC, Shao B. Analysis of total immunoglobulin E and specific immunoglobulin E of 3,721 patients with allergic disease. Biomed Rep 2015;3(4):573-7.
2. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113(5):832-6.